Clinicaltrials.gov identifier. RAF, PI3K and the RAL guanine exchange factor (RAL-GEF) were initially identified as essential components of RAS-mediated transformation in rodent cells. Human cell ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...

In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.

The review explores strategies to overcome this resistance, focusing on targeting downstream molecules within the RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. Furthermore, the study explores the ...

BBO-8520 is a direct inhibitor of KRAS G12C in both the “ON” and “OFF” states and is currently being evaluated in the Phase 1 ONKORAS-101 trial (NCT06343402) for patients with KRAS G12C ...

Verastem Oncology is currently conducting clinical trials with avutometinib with and without defactinib in RAS/MAPK-driven tumors as part of its Raf And Mek Program or RAMP. Verastem is currently ...

In this article, we will discuss the evidence for RAF and PI3K as key downstream RAS effectors, as well as the RAL guanine exchange factor, which is equally essential for transformation.